Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$71.18 -0.7%	$72.72	$57.52 ▼ $132.26	$27.91B	1.5	4.20 million shs	2.78 million shs
GMED Globus Medical	$72.58 -0.3%	$74.07	$49.33 ▼ $94.93	$9.98B	1.28	1.04 million shs	787,354 shs
IDXX IDEXX Laboratories	$433.99 -0.8%	$419.59	$356.14 ▼ $548.88	$35.17B	1.5	631,641 shs	909,572 shs
RMD ResMed	$234.06 -0.8%	$221.91	$179.42 ▼ $263.05	$34.38B	0.75	1.01 million shs	1.12 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	-0.67%	+7.67%	+5.08%	-19.39%	-42.75%
GMED Globus Medical	-0.38%	+4.69%	+0.13%	-21.89%	+43.58%
IDXX IDEXX Laboratories	-0.79%	+6.72%	+4.36%	+3.86%	-13.08%
RMD ResMed	-0.73%	+10.91%	+6.46%	-6.39%	+7.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.9468 of 5 stars	4.5	4.0	0.0	4.7	4.1	2.5	1.9
GMED Globus Medical	4.7863 of 5 stars	4.4	3.0	0.0	4.1	2.8	2.5	1.9
IDXX IDEXX Laboratories	4.4045 of 5 stars	3.4	3.0	0.0	3.7	3.5	2.5	1.3
RMD ResMed	4.3735 of 5 stars	3.3	1.0	3.3	4.6	2.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$99.00	39.08% Upside
GMED Globus Medical	2.75	Moderate Buy	$96.91	33.52% Upside
IDXX IDEXX Laboratories	2.78	Moderate Buy	$523.75	20.68% Upside
RMD ResMed	2.60	Moderate Buy	$258.83	10.58% Upside

Current Analyst Ratings Breakdown

Latest GMED, IDXX, RMD, and DXCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	RMD ResMed	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$274.00
4/24/2025	RMD ResMed	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$247.00 ➝ $255.00
4/24/2025	RMD ResMed	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$290.00 ➝ $285.00
4/24/2025	RMD ResMed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$286.00 ➝ $290.00
4/24/2025	RMD ResMed	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$260.00 ➝ $248.00
4/21/2025	RMD ResMed	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$280.00 ➝ $269.00
4/16/2025	RMD ResMed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$265.00
4/14/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$450.00 ➝ $420.00
4/11/2025	GMED Globus Medical	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$82.00 ➝ $80.00
4/10/2025	DXCM DexCom	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$85.00
4/9/2025	DXCM DexCom	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	6.92	$1.79 per share	39.75	$5.38 per share	13.23
GMED Globus Medical	$2.52B	3.96	$3.11 per share	23.32	$29.32 per share	2.48
IDXX IDEXX Laboratories	$3.90B	9.02	$10.87 per share	39.92	$19.48 per share	22.28
RMD ResMed	$5.02B	6.85	$9.28 per share	25.23	$35.77 per share	6.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.43	49.78	28.93	2.30	14.29%	30.14%	10.11%	5/1/2025 (Estimated)
GMED Globus Medical	$122.87M	$0.75	96.77	18.01	1.61	4.09%	10.83%	8.63%	5/8/2025 (Estimated)
IDXX IDEXX Laboratories	$887.87M	$10.67	40.67	31.96	3.41	22.78%	55.82%	26.48%	5/1/2025 (Estimated)
RMD ResMed	$1.02B	$8.91	27.63	22.59	1.53	25.34%	26.17%	18.60%	N/A

Latest GMED, IDXX, RMD, and DXCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMED Globus Medical	$0.74	N/A	N/A	N/A	$629.74 million	N/A
5/1/2025	Q1 2025	DXCM DexCom	$0.33	N/A	N/A	N/A	$1.02 billion	N/A
5/1/2025	Q1 2025	IDXX IDEXX Laboratories	$2.93	N/A	N/A	N/A	$998.25 million	N/A
4/23/2025	Q3 2025	RMD ResMed	$2.36	$2.37	+$0.01	$2.48	$1.28 billion	$1.29 billion
2/20/2025	Q4 2024	GMED Globus Medical	$0.74	$0.84	+$0.10	$0.19	$646.19 million	$657.29 million
2/13/2025	Q4 2024	DXCM DexCom	$0.50	$0.45	-$0.05	$0.38	$1.10 billion	N/A
1/30/2025	Q2 2025	RMD ResMed	$2.29	$2.43	+$0.14	$2.34	$1.27 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
GMED Globus Medical	N/A	N/A	N/A	N/A	N/A
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.12	0.91%	+7.63%	23.79%	13 Years

Latest GMED, IDXX, RMD, and DXCM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2025	RMD ResMed	quarterly	$0.53	0.9%	5/8/2025	5/8/2025	6/12/2025
1/30/2025	RMD ResMed	quarterly	$0.53	0.9%	2/13/2025	2/13/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.59	1.47	1.28
GMED Globus Medical	N/A	2.51	1.64
IDXX IDEXX Laboratories	0.28	1.31	0.95
RMD ResMed	0.13	3.33	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
GMED Globus Medical	95.16%
IDXX IDEXX Laboratories	87.84%
RMD ResMed	54.98%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
GMED Globus Medical	18.54%
IDXX IDEXX Laboratories	0.98%
RMD ResMed	0.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	7,600	392.11 million	389.60 million	Optionable
GMED Globus Medical	2,600	137.54 million	110.92 million	Optionable
IDXX IDEXX Laboratories	10,800	81.04 million	80.16 million	Optionable
RMD ResMed	8,160	146.87 million	145.82 million	Optionable

GMED, IDXX, RMD, and DXCM Headlines

Recent News About These Companies

Second Half Financial Partners LLC Cuts Stock Position in ResMed Inc. (NYSE:RMD)

April 29 at 7:30 AM | marketbeat.com

ResMed Inc. (NYSE:RMD) Shares Acquired by MML Investors Services LLC

April 29 at 4:37 AM | marketbeat.com

Marshall Wace LLP Decreases Holdings in ResMed Inc. (NYSE:RMD)

April 29 at 4:20 AM | marketbeat.com

Aquatic Capital Management LLC Makes New Investment in ResMed Inc. (NYSE:RMD)

April 28 at 7:03 AM | marketbeat.com

Morgan Stanley Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)

April 28 at 6:37 AM | markets.businessinsider.com

Virtus ETF Advisers LLC Invests $1.07 Million in ResMed Inc. (NYSE:RMD)

April 28 at 6:36 AM | marketbeat.com

Syon Capital LLC Takes $272,000 Position in ResMed Inc. (NYSE:RMD)

April 28 at 5:36 AM | marketbeat.com

Dark Forest Capital Management LP Purchases 1,257 Shares of ResMed Inc. (NYSE:RMD)

April 28 at 5:08 AM | marketbeat.com

Stifel Financial Corp Purchases 14,149 Shares of ResMed Inc. (NYSE:RMD)

April 28 at 4:54 AM | marketbeat.com

ResMed Inc. Files Quarterly Report, Reinforces Market Position

April 27 at 6:47 PM | tipranks.com

What is William Blair's Forecast for ResMed Q1 Earnings?

April 27 at 8:10 AM | marketbeat.com

Banco Bilbao Vizcaya Argentaria S.A. Raises Stock Position in ResMed Inc. (NYSE:RMD)

April 27 at 6:09 AM | marketbeat.com

ResMed Inc. (NYSE:RMD) Stock Holdings Lessened by State of Tennessee Department of Treasury

April 26 at 5:34 AM | marketbeat.com

Dimensional Fund Advisors LP Has $169.79 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

April 26 at 5:08 AM | marketbeat.com

First Trust Advisors LP Raises Stake in ResMed Inc. (NYSE:RMD)

April 26 at 4:56 AM | marketbeat.com

ResMed (NYSE:RMD) Shares Gap Up Following Dividend Announcement

April 26 at 1:15 AM | americanbankingnews.com

ResMed Inc’s Earnings Call Highlights Growth and Innovation

April 25, 2025 | tipranks.com

ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy?

April 25, 2025 | zacks.com

Buy These 5 Low-Leverage Stocks to Counter Market Volatility

April 25, 2025 | zacks.com

Pinebridge Investments L.P. Purchases 74,408 Shares of ResMed Inc. (NYSE:RMD)

April 25, 2025 | marketbeat.com

ResMed Inc. (NYSE:RMD) Stake Raised by Tower Research Capital LLC TRC

April 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED, IDXX, RMD, and DXCM Company Descriptions

DexCom NASDAQ:DXCM

$71.18 -0.48 (-0.67%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$71.75 +0.57 (+0.80%)

As of 09:26 AM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Globus Medical NYSE:GMED

$72.58 -0.22 (-0.30%)

Closing price 04/28/2025 03:59 PM Eastern

Extended Trading

$72.21 -0.37 (-0.51%)

As of 09:02 AM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

IDEXX Laboratories NASDAQ:IDXX

$433.99 -3.45 (-0.79%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$431.38 -2.62 (-0.60%)

As of 09:25 AM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

ResMed NYSE:RMD

$234.06 -1.82 (-0.77%)

Closing price 04/28/2025 03:59 PM Eastern

Extended Trading

$234.02 -0.03 (-0.01%)

As of 09:15 AM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time